Helix BioPharma Bolsters Board with Key Appointments for Nasdaq Uplisting

Helix BioPharma Corp., a clinical-stage oncology company, has announced strategic appointments to its Board of Directors and corporate secretary position, signaling a strong push toward capital markets advancement and a planned Nasdaq listing. Zachary T. Stadnyk, former TSX Life Sciences Lead, joins the Board, bringing over 15 years of experience in biotechnology, capital markets, and public company leadership. He has advised biotech issuers on public listings and capital formation, supported over $100 million in institutional financings, and contributed to major transactions like the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. Natalia L. Butterworth, Director, Corporate Secretarial and Governance at ARO Consulting Inc., has been appointed Corporate Secretary, adding over 15 years of governance and regulatory compliance expertise across pharmaceuticals, technology, and finance.

These appointments come as Helix intensifies its capital markets strategy, including preparations for a Nasdaq listing via the Multijurisdictional Disclosure System (MJDS). The company is also relocating its registered office from Toronto to Vancouver, British Columbia, to align with governance and capital markets infrastructure needs. CEO Thomas Mehrling emphasized that strengthening capital markets and governance capabilities is a key priority as Helix finalizes the clinical protocol for its lead candidate L-DOS47, a Tumor Defense Breaker™ antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased therapy sensitivity. The pipeline also includes next-generation bi-specific ADCs, LEUMUNA™ for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug.

Helix’s strategic moves underscore its commitment to advancing hard-to-treat cancer treatments while building investor confidence. The company’s focus on the tumor microenvironment and innovative therapies positions it for growth, with the Nasdaq uplisting expected to enhance visibility and access to capital. As noted in the original release on NEWMEDIAWIRE, these developments mark a pivotal phase for Helix, aiming to unlock shareholder value and bring near-term solutions to patients.